Latest California Healthline Stories
Evaluating President Joe Biden’s First 100 Days in Office
Presidential historians say that Joe Biden’s first 100 days in office — a somewhat arbitrary but frequently cited milestone — have included an above-average number of major accomplishments.
KHN’s ‘What the Health?’: Picking Up the Pace of Undoing Trump Policies
The Biden administration has started to speed efforts to reverse health policies forged under Donald Trump. Most recently, the administration overturned a ban on fetal tissue research and canceled a last-minute extension of a Medicaid waiver for Texas. That latter move may delay the Senate confirmation of President Joe Biden’s nominee to head the Medicare and Medicaid programs, as Sen. John Cornyn (R-Texas) seeks to fight back. Anna Edney of Bloomberg News, Rachel Cohrs of Stat and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Public Health Experts Worry About Boom-Bust Cycle of Support
Congress has poured tens of billions of dollars into public health since last year. While health officials who have juggled bare-bones budgets for years are grateful for the money, they worry it will soon dry up, just as it has after previous crises such as 9/11, SARS and Ebola. Meanwhile, they continue to cope with an exodus from the field amid political pressure and exhaustion that meant 1 in 6 Americans lost their local health department leader.
Expertos en salud pública temen que los fondos desaparezcan cuando termine la pandemia
El Congreso ha enviado miles de millones a los departamentos de salud para luchar contra covid. Pero históricamente, esta financiación se acaba cuando termina la emergencia sanitaria.
KHN’s ‘What the Health?’: Planning for Round Two
The ink is barely dry on the recent covid relief bill, but Democrats in Congress and President Joe Biden are wasting no time gearing up for their next big legislative package. Meanwhile, predictions of more states expanding Medicaid have proved premature. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Lauren Weber, who reported the latest KHN-NPR “Bill of the Month” episode.
In His Continued Sparring With Fauci, Sen. Rand Paul Oversimplified the Science
The Kentucky lawmaker was right that a recent study offered evidence that vaccination and previous infection appear to neutralize covid-19. But experts say that doesn’t mean people should be complacent.
Military Exposed to Toxic Fumes From Burn Pits Set to Get Bipartisan Boost
Democratic Sen. Kirsten Gillibrand and Republican Sen. Marco Rubio were set to roll out a bill Friday that could help unknown thousands of service members who are sick from toxic substances they were exposed to from burning garbage in Afghanistan, Iraq and other war zones.
Democrats Could Undo Trump Policies Faster, But They’re Not. Why?
The little-used Congressional Review Act allows a new administration and Congress to fast-track the repeal of regulations and other executive actions of the previous administration. But neither lawmakers nor the president are making any attempt to use it now.
KHN’s ‘What the Health?’: Getting Down to Work at HHS
After a bruising confirmation process, Xavier Becerra was sworn in as secretary of Health and Human Services this week. The Senate also confirmed the nominations of former U.S. Surgeon General Vivek Murthy to return to the post he held in the Obama administration, and former Pennsylvania health secretary Rachel Levine as assistant secretary for health. Levine is the first openly transgender person to receive Senate confirmation. Meanwhile, questions continue to swirl around the AstraZeneca covid vaccine, which some public health experts worry will create more hesitancy toward other vaccines.
Democrats Eye Medicare Negotiations to Lower Drug Prices
Progressive and conservative Democratic lawmakers, as well as President Joe Biden, are in favor of authorizing federal officials to negotiate with drugmakers over what Medicare pays for at least some of the most expensive brand-name drugs and to base those prices on the drugs’ clinical benefits. Such a measure could put Republicans in the uncomfortable position of opposing an idea that most voters from both parties generally support.